Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered as an oral solution for 28 days.
Epistemonikos ID: dd5ff6d2113c9591f2e80279a2d728e017cbb1f2
First added on: May 22, 2025